Tagged with HitGen

China Pharma News: CanSino’s Inhaled COVID-19 Vaccine Approval; HitGen/Unison’s Anti-Infectives Deal; Neukio Biotherapeutics Funding

China China Pharma News: CanSino’s Inhaled COVID-19 Vaccine Approval; HitGen/Unison’s Anti-Infectives Deal; Neukio Biotherapeutics Funding

China China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell therapy biotech Neukio Biotherapeutics. Neovii & Fosun Pharma sign deal to bring transplantation medicine to China (BioSpectum Asia) Switzerland-based…

China: Hitgen Aims to Strengthen its “Innovation Foundation” with UK & US Partnerships

China China: Hitgen Aims to Strengthen its “Innovation Foundation” with UK & US Partnerships

China PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical libraries (DEL) and their multipronged business strategy. Established in 2012, the company introduced the novel DEL technology platform to China. As Dr Li recounted, “it was not…

Chinese Biotech Strategies: Biologics or Small Molecules

China Chinese Biotech Strategies: Biologics or Small Molecules

China While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception in the 1980s, and presently, biologics represent a stunning eight out of the top ten best-selling drugs in 2019. In China, this sector has lagged behind developed…

Jin LI – Chairman & CEO, HitGen, China

China Jin LI – Chairman & CEO, HitGen, China

China Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion. By now, we have a platform of over 500…

China Pharma News Roundup May 11th 2020

China China Pharma News Roundup May 11th 2020

China Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi’s out-licensing of a potential COVID-19 treatment to Lilly, and Ascentage being granted US FDA orphan drug status for its leukaemia candidate. Hong Kong IPOs Pick Up the Pace as China Restarts https://www.bloombergquint.com/onweb/hong-kong-ipos-pick-up-the-pace-as-china-restarts-ecm-watch Initial public…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page